Rocket Lab's Launch Cadence Accelerates as Wall Street Debates What the Stock Is Worth

Rocket Lab's 16th Electron launch of 2026 comes as analysts stay bullish, ARK buys, insiders sell, and shares sit 59% below their 52-week high.

Rocket Lab marked its 16th Electron launch of 2026 on Friday, sending an Earth-observation satellite into orbit for an undisclosed customer on a mission dubbed "Happily Ever Faster." Another flight is slated before the month is out, this time for a commercial satellite constellation operator — a schedule that says as much about the company's ambitions as any earnings report.

The pace has been relentless. Just days into September, Rocket Lab completed its 94th Electron mission overall, the eleventh successful launch for Japanese customer Synspective. A company that knocks out two missions in quick succession while simultaneously rolling out a new product hardly fits the profile of a business in trouble. Last week it unveiled IMM Apex, a germanium-free solar cell for space applications boasting an initial efficiency of 31.5 percent at 40 percent less mass — evidence that Rocket Lab now sees itself as a supplier to the broader space industry, not merely a launch operator.

Analysts See Room to Run

Raymond James initiated coverage on Friday with an Outperform rating and an $80 price target. Analyst Brian Gesuale pointed to the Neutron rocket and the planned Iridium/Mynaric expansion as the central growth drivers, while flagging execution, integration and margin risks. The call extends a run of largely bullish analyst sentiment. Berenberg kicked off its coverage in August with a Buy rating and an $83 target, citing falling launch costs and the company's hard-to-replicate vertical integration. Bank of America trimmed its target from $115 to $110 but kept its buy recommendation intact.

Those targets sit well above where the stock currently trades — a gap that captures the tension between analysts' fundamental view and the recent price action.

The Numbers Behind the Optimism

The bullish case rests on tangible operational progress. Rocket Lab posted second-quarter revenue of $234.1 million, up roughly 62 percent year over year, while its order backlog climbed to a record $2.36 billion. For the third quarter, management guided to revenue of $250 million to $265 million with a GAAP gross margin of 29 to 31 percent. Adjusted EBITDA is still expected to show a loss of $17 million to $23 million.

Institutional interest has followed. Cathie Wood's ARK Investment Management added roughly 681,000 shares across three ETFs over two days in early September — a commitment of more than $44 million and the fund's largest disclosed build-up in that stretch. The Arizona State Retirement System boosted its stake by 205 percent in the second quarter, adding 267,742 shares to reach 398,369. Manufacturers Life Insurance Company also opened a new position. These are not short-term traders but addresses allocating over multi-year horizons.

Insiders Head for the Exits

Running counter to that institutional buying, several executives have been selling. CFO Adam C. Spice offloaded 140,157 shares in early September at a weighted average price of $62.63, a transaction worth about $8.8 million. Chief Operations Officer Frank Klein and General Counsel Arjun Kampani also parted with shares in the mid-five-figure range in late August. All of the transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them routine portfolio management rather than a spontaneous signal on business conditions — though the divergence between insider selling and institutional buying remains a data point worth watching.

A Stock Out of Step With Its Own Story

The market's ambivalence is written plainly in the share price. The stock rose 2.1 percent on Friday to close at EUR 54.50, a small sign of life after a bruising month. On a weekly basis it is down 1.6 percent, and over 30 days it has shed 23 percent. The shares now sit roughly 59 percent below their 52-week high of EUR 133.80.

That disconnect between operational tempo and stock performance is no statistical accident — it says something about the entire new-space sector. Growth names with heavy investment requirements and long payback cycles come under pressure whenever rate uncertainty rises, regardless of how many rockets actually leave the pad. Rocket Lab delivers the facts; the market delivers the nerves.

For investors, the picture remains genuinely mixed: robust revenue, a record backlog and optimistic price targets on one side; meaningful recent losses and management-level selling on the other. Whether the company's fundamental strength eventually shows up in the share price will depend far less on the next Electron launch than on how long the market is willing to prioritize growth over profitability — and on the progress of the Neutron rocket. That question is likely to shadow the stock for longer than any single mission.